Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding
The use of gastroprotective agents has allowed significant progress in the prevention of upper gastrointestinal bleeding (UGIB) associated with non-steroidal anti-inflammatory drugs (NSAIDs) and antiplatelet agents. Nevertheless, some concerns remain regarding the gastroprotective dosage and treatment duration. Our aim was to study the effect of gastroprotective agents in UGIB induced by NSAIDs and single- or dual-antiplatelet therapy.
A multicenter case-control study was conducted including 577 cases diagnosed with UGIB and 1343 sex-, age-, and hospital-matched controls. To estimate exposure to NSAIDs and gastroprotective agents, consumption was calculated for the 4 weeks prior to hospital admission in terms of defined daily doses (DDDs). Risk groups for UGIB induced by NSAIDs and single- or dual-antiplatelet therapy were defined as a function of each drug dose, use of gastrointestine-damaging drugs, and risk factors for UGIB. Odds ratios (ORs) with 95% confidence intervals (CIs) were adjusted for single- (model 1) and dual- (model 2) antiplatelet therapy.
Full adherence (> 0.80DDD) to proton pump inhibitors (PPIs) was the only gastroprotective therapy that significantly reduced the risk of UGIB, considering NSAID risk (OR: 0.53; 95% CI: 0.30–0.95) and dose (OR: 0.48; 95% CI: 0.27–0.87) with ORs adjusted for single-antiplatelet therapy (model 1) and NSAID risk (OR: 0.55; 95% CI: 0.31–0.98) and dose (OR: 0.49; 95% CI: 0.28–0.89) with ORs adjusted for dual-antiplatelet therapy (model 2).
These results reinforce the recommendation of adding a PPI at effective doses (full adherence) to prevent UGIB induced by NSAIDs, or single- or dual-antiplatelet therapy.
KeywordsUpper gastrointestinal Hemorrhage Acid-suppression therapy Prospective case-control
Guarantor of the article
C Aguirre and B Ruiz.
A Figueiras, A Carvajal, L Ibañez, A Conforti, and C Aguirre: design of the research study, obtained funding; critical revision of the manuscript for important intellectual content. B Ruiz, A Estany-Gestal, L Rodella, P Ruiz: acquisition of data. B Ruiz, U Aguirre, C Aguirre: statistical analysis. B Ruiz and C Aguirre: drafting of the manuscript. MM de Pancorbo, X Vidal, and LH Martin: critical revision of the manuscript for important intellectual content. All authors approved the final version of the manuscript.
In Spain, this study was funded by the national Health Research Fund (Fondo de Investigación Sanitaria) (Ministry of Economy and Competitiveness), grant numbers PI 02/1512, 02/0661/, 02/1364, and 02/1572 and by the Department of Health of the Basque Country, grant numbers 03/11092 and 11/111103; as well as supported in part in Catalonia by the Novartis, Pfizer and Dr. Esteve pharmaceutical companies. In Italy, the study was funded by unrestricted grants from Pfizer Italy and Department of Medicine and Public Health, University of Verona. The funders had no role in the study design, data-collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
The study protocol was approved by the institutional review boards of all participating hospitals. All patients were provided with information about the study and gave written informed consent.
Conflict of interests
The authors declare that they have no conflict of interest.
- 6.Hermansson M, EkedahlA RJ, Zilling T (2009) Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol 9:25. https://doi.org/10.1186/1471-230X-9-25 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Zeitoun JD, Rosa-Hézode I, Chryssostalis A, Nalet B, Bour B, Arpurt JP, Denis J, Nahon S, Pariente A, Hagège H, Groupe des Hémorragies Digestives Hautes de l’ANGH (2012) Epidemiology and adherence to guidelines on the management of bleeding peptic ulcer: a prospective multicenter observational study in 1140 patients. Clin Res Hepatol Gastroenterol 36:227–234CrossRefGoogle Scholar
- 11.Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquivias G, Perez-Aísa Á, Spanish Society of Rheumatology; Spanish Association of Gastroenterology; Spanish Society of Cardiology et al (2014) Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document elaborated by nominated experts of three scientific associations (SER-SEC-AEG). Reumatol Clin 10:68–84. https://doi.org/10.1016/j.reuma.2013.10.004 CrossRefPubMedGoogle Scholar
- 12.Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents et al (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J Am Coll Cardiol 52:1502–1517CrossRefGoogle Scholar
- 13.Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, ACCF/ACG/AHA (2010) ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on expert consensus documents. Circulation 122:2619–2633CrossRefGoogle Scholar
- 19.Vidal X, Ibáñez L, Vendrell L, Conforti A, Laporte JR, Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding (2008) Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 31:159–168CrossRefGoogle Scholar
- 20.TrinityBiotech. Helicobacter pylori test. Available at: https://www.trinitybiotech.com/news-events/news/trinity-biotech-announces-ce-marking-of-uni-gold-h-pylori-antigen-point-of-care-test/. Accessed 9 July 2018
- 22.Definition and general considerations of DDD [on line], last updated 2018–02-07, WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Available at: http://www.whocc.no/ddd/definition_and_general_considera/. Accessed 9 July 2018
- 24.Valkhoff VE, van Soest EM, Mazzaglia G, Molokhia M, Schade R, Trifiro G, Goldstein JL, Hernandez-Diaz S, Kuipers EJ, Sturkenboom MCJM (2012) Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study. Arthritis Rheum 64:2792–2802CrossRefGoogle Scholar
- 30.Anonymous (2011) Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int 20:216–219Google Scholar